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Abstract: Background: We performed a nested case-control study of Thai women prescribed nevirapine-based 
antiretroviral therapy (ART) to determine if development of rash or hepatotoxicity during the first 24 weeks of treatment 
is associated with plasma nevirapine concentrations. 
Method: From May 2005-January 2007, we enrolled 217 women initiating nevirapine-based ART in Thailand. Cases (n = 
54) were women who during the first 24 weeks of treatment with nevirapine developed rash (any grade, n = 42) or 
hepatotoxicity ( grade 2, n = 22, [10 had both]). Controls were the next enrolled woman who was confirmed not to meet 
the case definition during the first 24 weeks. Nevirapine concentrations after the two week lead-in dose of 200 mg once 
daily were compared between cases and controls by Wilcoxon rank-sum tests. 
Results: We found no difference in Week 2 pre-dose nevirapine concentrations: cases median = 3,528 ng/mL (n = 24), 
controls median = 3,150ng/mL (n = 30), p = 0.5. Cases had higher post-dose nevirapine concentrations (median = 6,150 
ng/mL, n = 21) than controls (median = 4,746 ng/mL, n = 20, p = 0.02). When limited to cases who developed a rash at 
Week 2, we found no differences in the pre-dose (median = 3,270 ng/mL, n = 12, p = 0.9) or post-dose nevirapine 
concentration (median = 5,443 ng/mL, n = 9, p = 0.4) compared with controls. 
Conclusions: We cannot conclude definitively that nevirapine concentrations at two weeks of therapy are associated with 
rash or hepatotoxicity. It is unlikely that therapeutic drug monitoring at that time will improve identification of patients at 
risk for rash or hepatotoxicity. 
Keywords: Adverse effect, antiretroviral, hepatotoxicity, nevirapine, rash, Thailand. 
INTRODUCTION 
 An estimated 7-15% of patients receiving nevirapine 
experience drug rash or toxicity, although higher rates have 
been reported in Thai populations [1,2]. One possible 
explanation is that Thai patients may have higher plasma 
concentrations of nevirapine than North American or 
European patients when treated with the same dosage. The 
TREAT Asia cohort has found that a significant proportion 
of drug discontinuations (23%) are attributed to nevirapine- 
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induced rashes [2]. These drug discontinuations have 
programmatic implications for national treatment programs 
since nevirapine is part of the first-line regimen in many 
countries. 
 The original dosing regimen of nevirapine was developed 
in western countries in the 1990s and consists of a standard 
lead-in dose of 200 mg once daily for the first two weeks of 
therapy followed thereafter by 200 mg twice daily. This 
lower lead-in dose is given to minimize the risk of adverse 
reactions to nevirapine observed in pre-clinical trials [3,4]. 
Aftera two-week dosing period, auto-induction of hepatic 
P450 isoenzymes results inan approximate two-fold increase 
in nevirapine clearance [5]. 
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 The usual target trough (Cmin) plasma concentration for 
nevirapine considered necessary for optimal virologic 
response is >3,000 ng/mL [6]. The association of nevirapine 
concentrations and toxicity is still under debate. One study in 
Amsterdam found a significant association between the 
development of rash and nevirapine concentrations greater 
than 5,300 ng/mL [7]. A study in Spain found an association 
between increased liver transaminases and nevirapine trough 
concentrations greater than 6,000 ng/mL [8]. A study in 
Italy, however, did not find an association between 
nevirapine concentrations and hepatotoxicity [9]. The multi-
country “2NN Study” which included patients from 
Thailand, South Africa, South America, and other Western 
countries examined the pharmacokinetics of nevirapine and 
the relation to adverse events [10,11]. For patients receiving 
the standard dose of nevirapine 200 mg twice daily, the 
average Cmax was 7,030 ng/mL and Cmin was 4,950 ng/mL 
across the entire cohort. The investigators found that patients 
from Thailand had 22% lower clearance of nevirapine than 
patients from South America or Western countries. They 
reported no association between rash, or other adverse 
events, and nevirapine concentrations [10]. Another study 
conducted in Thailand found the mean nevirapine 
concentration in patients taking nevirapine-based ART 
drawn on average approximately 9 hours after a dose to be 
8,720 ng/mL [12]; this value was higher than the Cmax 
reported in the 2NN Study from multiple countries [10]. The 
average concentrations drawn between 0 – 9.9 hours was 
9,900 ng/mL and between 10 – 14 hours after a dose 
(indicative of trough concentrations) was 7,960 ng/mL [10]. 
 The NNRTI Response study was a multi-site 
observational study conducted in Thailand, Zambia, and 
Kenya [13]. This nested case-control sub-study from the 
Thailand portion of the study was undertaken to determine if 
plasma nevirapine concentrations were associated with the 
development of rash or hepatotoxicity during the first 24 
weeks of nevirapine-based ART. 
METHODS 
Definition of Cases and Controls 
 A total of 217 HIV-infected women were enrolled in 
Bangkok, Thailand at two sites – Siriraj Hospital and 
Rajvithi Hospital [13]. At enrollment and at weeks 2, 4, 8, 
16, and 24, participants had serum alanine transaminase 
(ALT) and aspartate transaminase (AST) measured and were 
evaluated clinically for signs and symptoms of hepatitis and 
rash. We graded adverse events including hepatotoxicity and 
rash according to the National Institutes of Health’s Division 
of AIDS guidelines as previously reported [14,15]. 
 Cases in this analysis were women who during the first 
24 weeks of treatment with nevirapine-based HAART 
developed 1) any grade of rash or 2) an increase of at least 
one grade from baseline in ALT or AST to at least grade 2. 
Only rash or increase in ALT or AST that the study team 
determined to be “possibly”, “probably”, or “definitely” 
related to nevirapine, considering character and timing of the 
reaction, was considered. Controls were selected as the next 
enrolled participant at the same study site who was 
confirmed not to have met the case definition during the first 
24 weeks of treatment. 
 Clinical care was provided by physicians with expertise 
in HIV disease at each of the study hospitals. The study 
protocol did not direct individual treatment decisions and the 
clinicians used their discretion to continue nevirapine 
through a mild reaction, to interrupt nevirapine therapy and 
restart it, or to change therapy substituting either efavirenz or 
a protease inhibitor for nevirapine. 
Specimens and Bioanalytical Methods 
 Blood specimens were collected in Becton Dickinson 
Vacutainer® tubes containing ethylenediaminetetraacetic 
acid as an anticoagulant and were stored at room temperature 
until transported on ice to the laboratory. Plasma was 
separated and frozen within six hours of blood collection. 
The time and date of specimen collection was recorded by 
study nurses. CD4 cell counts were measured as previously 
described [13]. We tested for hepatitis B surface antigen and 
for hepatitis C antibody with Murex Enzyme Immunoassays 
(Abbott Diagnostics, Dartford, UK). Stored plasma 
specimens collected at 2, 4, and 8 weeks of the study were 
assayed for nevirapine, stavudine, and lamivudine 
concentration. 
 Stavudine, lamivudine, and nevirapine concentrations in 
plasma specimens were determined using an LC-MS/MS 
method [High Performance Liquid Chromatography (HPLC, 
AcquityTM Ultra Performance LC, Waters Co., Ltd. USA), 
Mass Spectrometer (Quattro Premier XE, Micromass 
Technologies, UK) and Masslynx v 4.1 software (Micromass 
Technologies, UK)]. The method had been developed and 
validated by the Department of Pharmacology, Faculty of 
Medicine Siriraj Hospital, Mahidol University (Bangkok, 
Thailand) according to the US FDA Guidance for Industry: 
Bioanalytical Method Validation (2001). The validation 
demonstrated that the method was reliable and reproducible 
for the intended use with respect to selectivity, sensitivity, 
linearity, accuracy, precision, and stability of the drugs in 
plasma. The assay had a linearity range of 1-8,000, 1-12,500, 
and 1-25,000 ng/mL for stavudine, lamivudine, and 
nevirapine, respectively. 
Assignment of Pre- and Post-Dose Nevirapine Concentrations 
 Participants took versions of locally produced 
medications as either a fixed-dose combination of stavudine 
(30 or 40 mg), lamivudine (150 mg), and nevirapine (200 
mg) [GPO-vir, Government Pharmaceutical Organization 
(GPO), Bangkok, Thailand] or as individual formulations of 
stavudine (30 or 40 mg) and lamivudine (150 mg) (GPO, 
Bangkok, Thailand). To accommodate the need for a two-
week lead-in phase of nevirapine 200 mg daily, women took 
GPO-vir once daily in the morning and stavudine and 
lamivudine as individual products in the evening. After two 
weeks, women took GPO-vir twice daily. Adherence support 
and counseling was provided by the clinical staff and study 
nurses who met with each participant at each study visit to 
record adherence to medications and to provide additional 
counseling. Upon enrolling in the study, participants were 
instructed to choose a time of day for ingestion of 
antiretroviral drugs that would best meet their needs. 
 Although the time when antiretroviral medications were 
generally given (e.g., 9 AM and 9 PM) was known, the 
precise time of the most recent dose of medications was not 
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recorded. We relied on the concentrations of stavudine and 
lamivudine (while not considering the corresponding 
nevirapine concentrations) to determine if a plasma specimen 
was classified as pre-dose or post-dose. Stavudine and 
lamivudine are both renally cleared with plasma half-lives of 
~1 hour [16] and ~5-7 hours [17], respectively. There is 
substantial fluctuation in the plasma concentrations of 
stavudine and lamivudine over a 12-hour dosing interval. 
The typical peak and trough stavudine concentrations 
following twice daily doses of 30 or 40 mg are >600 ng/mL 
(range ~600 – 1,200) and <25 ng/mL (range, undetectable - 
<200) [18-21], respectively. The same values for lamivudine 
following twice daily doses of 150 mg are >1000 ng/mL 
(range ~500 – 2,000) and <200 (range, ~<50 – 500) [22-24], 
respectively. In contrast, there is relatively little fluctuation 
in plasma nevirapine concentrations over a 12-hour dosing. 
Nevirapine is metabolized by hepatic cytochrome P450 
isoenzymes, primarily CYP3A4, and auto-induces its own 
metabolism so that the terminal half-life decreases from ~45 
hours after the first dose to ~25-30 hours following multiple 
dosing [25]. 
 Considering these pharmacokinetic data, we 
characterized pre-dose specimens as those that had 
concentrations of: 1) stavudine 200 ng/mL and lamivudine 
500 ng/mL, or 2) stavudine 25 ng/mL and lamivudine 
<650 ng/mL. The latter was chosen to accommodate 
specimens with very low stavudine concentrations and 
relatively low lamivudine concentrations in order to include 
more data points in the pre-dose group. Post-dose specimens 
had concentrations of stavudine >200ng/mL and lamivudine 
>500 ng/mL. Specimens that did not meet either of these 
definitions were censored from the analyses. 
Statistical Analysis 
 We calculated standard summary statistics of the enrollment 
characteristics including counts, proportions, medians, and 
quartile ranges. Nonparametric Wilcoxon rank-sum tests were 
used to compare the medians of selected baseline variables 
between cases and controls. Chi-square or Fisher’s exact tests 
were used to compare categorical covariates. For comparisons 
of nevirapine concentrations between two groups of 
participants, we used Wilcoxon rank-sum tests. Women had at 
most one nevirapine concentration determined for analysis 
(either pre-dose or post-dose) at each of week 2, 4, or 8. Our 
primary comparison was of the plasma nevirapine 
concentrations at week 2, where all but one woman had a 
specimen available. Adverse effects present at week 2 or week 4 
that resulted in substitution of another drug for nevirapine 
confounded statistical comparisons at week 4 and week 8 (i.e., 
nevirapine had been discontinued before the week 4 and week 8 
visit for these women), thus we did not make statistical 
comparisons using those data. We present the raw values for 
concentrations at weeks 4 and 8 for visual inspection. We also 
tested for differences in nevirapine concentrations according to 
participants’ use of fluconazole and serum hepatitis B surface 
antigen status. We plotted nevirapine concentrations versus 
body-mass index and calculated Pearson’s correlation 
coefficient to determine if there was a linear relationship. All of 
these statistical calculations were performed using SAS 
software, version 9.2 (SAS Institute, Inc., Cary, North 
Carolina). 
 Written informed consent to participate in this study was 
obtained from each participant according to the protocol 
approved by the Ethical Review Committee for Research in 
Human Subjects of Thailand Ministry of Public Health 
(Rajvithi Hospital) and the Institutional Review Boards of 
the Siriraj Hospital and of the CDC. 
RESULTS 
 We identified 54 cases and selected 54 controls (Table 
1), which included 34 cases and 34 controls from among 115 
women enrolled at Rajvithi Hospital and 20 cases and 20 
controls from among 102 women enrolled at Siriraj Hospital 
(p = 0.26 Chi-square test for proportion of cases by site). 
Among the 54 cases, 42 (78%) women had rash and 22 
(41%) had hepatotoxicity; 10 (19%) women had both rash 
and hepatotoxicity. The rash was first noted at week 2 for 25 
women, at week 4 for eight women, at week 8 for seven 
women, and at week 16 for two women. Hepatotoxicity was 
first noted at week 2 for eight women, at week 4 for 11 
women, at week 8 for one woman, and at week 16 for two 
women. There were 270 samples assayed for lamivudine, 
stavudine, and nevirapine. We assayed samples from all 54 
controls at weeks 2, 4, and 8 and from cases at week 2 for 53 
women (one woman had no sample available), at week 4 for 
35 women (19 had discontinued nevirapine), and at week 8 
for 20 women (34 had discontinued nevirapine). Based on 
the stavudine and lamivudine concentrations, we classified 
136 (50%) samples as pre-dose, 108 (40%) samples as post-
dose, and 26 (10%) as samples unclassifiable or censored. 
Median pre-dose concentrations were: stavudine 8 ng/mL 
(interquartile range [IQR], below level of quantification – 
22), lamivudine 191 ng/mL (IQR, 141 – 293), and nevirapine 
4,377 ng/mL (IQR, 3,190 – 6,234). Median post-dose 
concentrations were: stavudine 643 ng/mL (IQR, 448 – 914), 
lamivudine 2,038 ng/mL (IQR, 1,458 – 2,878), and 
nevirapine 6,671 ng/mL (IQR, 5,059 – 8,934). The median 
post-dose nevirapine concentration was higher than the pre-
dose nevirapine concentration at week 2 (p <0.001), week 4 
(p <0.01), and week 8 (p = 0.02) indicating the assignment of 
pre-dose and post-dose based on the concentrations of 
stavudine and lamivudine was valid (Fig. 1). 
Nevirapine Concentrations in Cases and Controls 
 We found no difference in pre-dose plasma nevirapine 
concentrations at week 2 comparing cases (3,528 ng/mL, n = 
24) with controls (3,150, n = 30, p = 0.5) (Fig. 1). Post-dose 
nevirapine concentrations were higher for cases who 
developed rash at any time (median = 6,150 ng/mL, n = 21) 
versus controls (median = 4,746 ng/mL, n = 20, p = 0.02); 
however, when limited to cases who developed a rash at 
week 2, we observed no differences in either pre-dose or 
post-dose week 2 plasma nevirapine concentrations: median 
3,270 ng/mL (n = 12, p = 0.9) and median 5,443 ng/mL (n = 
9, p = 0.4), compared with the same controls, respectively. 
When limiting the analysis to only women who had 
hepatotoxicity, we found that they had similar pre-dose and 
post-dose plasma nevirapine concentrations at week 2 
compared with controls. Women who developed both rash 
and hepatotoxicity likewise had similar pre-dose and post-
dose nevirapine concentrations compared with controls at 
week 2. 
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Investigation of Other Co-Factors that Might be Associated 
with Nevirapine Concentrations 
 Fluconazole was prescribed for 32 patients at the time of 
the week 2 visit, for 26 patients at week 4, and for 23 
patients at week 8. There were no differences in pre-dose or 
post-dose nevirapine concentrations among patients taking 
fluconazole compared with patients not taking fluconazole at 
weeks 2, 4, or 8. There were also no differences in pre-dose 
and post-dose nevirapine concentrations at weeks 2, 4, or 8 
comparing women who were positive for hepatitis B surface 
antigen versus negative. There were too few women who 
were hepatitis C antibody positive to make meaningful 
comparisons. There was a marginally significant relationship 
between body-mass index and the post-dose plasma 
nevirapine concentration at week 2 (Pearson’s r = -0.31, p = 
0.051), but not at week 4 (r = 0.02, p = 0.90) or week 8 (r = 
0.09, p = 0.64), and no significant relationship between 
body-mass index and pre-dose nevirapine concentrations at 
week 2 (r = -0.013, p = 0.92), week 4 (r = -0.06, p = 0.69) or 
week 8 (r = 0.20, p = 0.25) (Fig. 2). 
Strata of Nevirapine Concentrations 
 At week 2 while on nevirapine 200 mg once daily, pre-
dose nevirapine concentrations ranged from <3,000 ng/mL 
for 39% of women to 9,000 ng/mL for 2% of women. Post-
dose concentrations ranged from <3,000 ng/mL for 12% of 
women to 9,000 ng/mL for 15% of women (Table 2). At 
week 2, cases were not more likely than controls to have a 
pre-dose concentration 6,000 ng/mL (p = 0.78 by Fishers 
exact test; sensitivity = 0.13, specificity = 0.93, predictive 
value positive = 0.60, predictive value negative = 0.57) or a 
post-dose nevirapine concentration 9,000 ng/mL (p = 0.18, 
sensitivity = 0.24, specificity = 0.95, predictive value 
positive = 0.83, predictive value negative = 0.54). At weeks 
4 and 8 (while on nevirapine 200 mg twice daily), there were 
fewer pre-dose or post-dose nevirapine concentrations 
<3,000 ng/mL. Nevirapine concentrations 9,000 ng/mL 
were found at week 4 for 13% of pre-dose and 46% of post-
dose observations and at week 8 for 11% of pre-dose and 
13% of post-dose concentrations. 
Strata of Nevirapine Concentrations and Effect on 
Subsequent Virologic Response 
 At week 2, a pre-dose nevirapine concentration <3,000 
ng/mL was found for 21 (39%) of 54 women and a post-dose 
nevirapine concentration <3,000 ng/mL was found for 5 
(12%) of 41 women (Table 2). After week 2, an additional 5 
women had a pre-dose (n = 4) or post-dose (n = 1) 
nevirapine concentration <3,000 ng/mL for a total of 31 
women who ever had a measured nevirapine concentration 
below the usual targeted threshold considered optimal for 
Table 1. Characteristics at Enrollment of Women who Developed Rash or Hepatotoxicity During the First 24 Weeks of 
Nevirapine-Based Antiretroviral Treatment (Cases) and Selected Controls, Bangkok, Thailand, 2005-2007 
 
Enrollment Characteristic Cases (n = 54) Controls (n = 54) p-Value 
Age (years) Median (range) 31 (23-50) 31 (24-55)  0.8 
Weight (kg) Median (range) 50.5 (31.5-74) 50 (30-97) 0.3 
Body Mass Index (kg/m
2
) Median (range) 21.0 (12.6-29.3) 21.1 (13.3-37.9) 0.4 
World Health Organization Stage      
 Stage 1 N 16 23  
 Stage 2 - Mild N 19 15  
 Stage 3 - Moderate N 8 8  
 Stage 4 - Severe N 11 8  
HIV Viral Load (copies/ml) Median (range) 67,558 (2,059 - >750,000) 91,427 (852 - >750,000) 0.9 
CD4 count (cell/ L) Median (range) 148 (0-330) 138 (0-390) 0.7 
Hepatitis B Surface Antigen Positive   N 8 8 1.0 
Hepatitis C Antibody Positive N 4 2 0.7 
     
Characteristic of Toxicity     
Rash Grade   n/a  









Hepatotoxicity Grade   n/a  
 2 (2.5 – 4.99 x ULN*)  
3 (5.0 – 9.99 x ULN) 





*ULN – upper limit of normal for ALT or AST result. 
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maintaining virologic control. Viral load was available at 
week 24 for 98 women in this analysis who continued on 
NNRTI-based ART (10 women were changed to a protease 
inhibitor or dropped out of the study). Viral load was <400 
copies/mL for 29 (100%) of 29 women who ever had a pre-
dose or post-dose nevirapine concentration <3,000 ng/mL 
and for 64 (93%) of 69 women who never had a pre-dose or 
post-dose nevirapine concentration <3,000 ng/mL (p = 0.3). 
 
Fig. (1). Nevirapine Concentrations at 2, 4, and 8 Weeks after Starting Treatment, Bangkok, Thailand, 2005-2007.  
Box-whisker plots (center line = median, top and bottom of box = interquartile range, ends of vertical line = minimum and maximum values) 
of pre-dose and post-dose plasma nevirapine concentrations at 2, 4, and 8 weeks after starting treatment for women with hepatotoxicity or 
rash (cases) and women without hepatotoxicity or rash (controls) during the first 24 weeks of nevirapine-based antiretroviral therapy. 
Participants received nevirapine 200 mg once daily for the first 2 weeks, then 200 mg twice daily.  
 Pre-Dose Post-Dose 
 Case Control p-Value Case Control p-Value 
Week n NVP n NVP  n NVP n NVP  
2 24 3,528 30 3,150 0.5 21 6,150 20 4,746 0.02 
4 15 5,995 31 5,703 - 17 9,393 20 7,351 - 
8 9 6,078 27 4,363 - 8 6,286 22 6,766 - 
NVP = median nevirapine concentration (ng/mL) 
p-value is by Wilcoxon test comparing nevirapine concentration for cases versus controls at week 2. We present the raw values of concentrations at weeks 4 and 8, without statistical 
comparisons, for visual inspection. 
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DISCUSSION 
 Among Thai women, rash or hepatotoxicity during the 
first 24 weeks of NNRTI-based ART was associated with 
higher post-dose, but not pre-dose, plasma nevirapine 
concentrations at week 2 while taking nevirapine once daily. 
There was a marginal association of lower body-mass index 
with higher post-dose nevirapine concentrations at week 2, 
although this finding must be interpreted cautiously since the 
body-mass index only explained approximately 9% of the 
variation seen in nevirapine concentrations at this time point. 
 A higher post-dose nevirapine concentration after 2 
weeks of the recommended lead-in dose of 200 mg daily 
suggests that persons who will develop rash or 
hepatotoxicity may have elevated concentrations of 
nevirapine soon after starting nevirapine. However, an 
elevated post-dose concentration at week 2 alone does not 
appear to be sufficient to explain these reactions, since many 
 
Fig. (2). Nevirapine Concentrations Plotted against Body-mass Index at 2, 4, and 8 Weeks after Starting Treatment, Bangkok, Thailand, 
2005-2007. Nevirapine post-dose (2a) and pre-dose (2b) concentrations at week 2 (closed circle), week 4 (plus sign), and week 8 (open 
triangle) after starting treatment. There was a marginally significant relationship between body-mass index and nevirapine concentration for 
post-dose at week 2 (Pearson’s r = -0.31, p = 0.051), but not for pre-dose at week 2 (r = -0.013, p = 0.92). We present the raw values of 
concentrations at weeks 4 and 8 for visual inspection. The horizontal dashed line is drawn at a concentration of 3,000 ng/mL, the usual 
minimum target trough plasma concentration for nevirapine. There was one additional woman with a body-mass index of 37.9 kg/m
2
 who 
had pre-dose nevirapine concentrations at week 2 of 2,317 ng/mL, at week 4 of 6,226 ng/mL, and at week 8 of 5,245 ng/mL; these outlier 
values were excluded to optimize clarity of the figure. All women with specimens that could be characterized as pre-dose or post-dose 
measurements are represented. 
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patients had post-dose concentrations >9,000 ng/mL at either 
weeks 2, 4, or 8, yet did not develop rash or hepatotoxicity. 
We observed extremely wide inter-patient variability in 
nevirapine concentrations at weeks 2, 4, and 8. At week 2, 
following the once daily 200 mg lead-in dose, nevirapine 
concentrations were ~30-40% lower than those at weeks 4 
and 8 after the dose had been escalated to 200 mg twice 
daily. It is reassuring that a nevirapine concentration <3,000 
ng/mL measured at week 2 was not associated with virologic 
failure while on NNRTI-based ART at week 24. 
 Nevirapine-associated rash, hepatotoxicity, and rash-
associated hepatotoxicity typically occur in the first few weeks 
to months of therapy; patients who tolerate nevirapine for the 
first few months will likely tolerate it indefinitely [2]. Some 
studies have supported an association between risk for 
hepatotoxicity and CD4 cell count 250 cells/ L in women 
[26,27] but others have not [14,28]. We have previously 
demonstrated from the parent study of this sub-study that 
among women taking nevirapine-based ART, severe 
hepatotoxicity and rash-associated hepatotoxicity were 
predicted by abnormal baseline ALT or AST results but not by a 
CD4 count 250 cells/ L [14]. Co-infection with viral hepatitis 
B or C has also been associated with hepatotoxicity from 
antiretroviral therapy in some [29,30] but not all studies [30,31]. 
 We did not record the precise time of ingestion of the 
antiretroviral drug in relation to the time the blood sample was 
taken. We characterized the nevirapine concentrations as either 
pre-dose or post-dose based on the concentration of stavudine 
and lamivudine from the same sample. The rationale for doing 
so was strengthened by the fact that nevirapine, stavudine, and 
lamivudine were taken simultaneously in the same fixed-dose 
combination tablet and the three drugs have relatively different 
pharmacokinetic properties. Our sample size for any one 
comparison was smaller than if we had a priori designed the 
study to collect all pre-dose samples. This limited our ability to 
detect relatively small differences in nevirapine concentrations 
between cases and controls. Likewise, our comparisons for 
other co-factors associated with nevirapine concentrations (e.g., 
concomitant fluconazole use, hepatitis B surface antigenemia) 
were limited by small numbers for comparisons. We had to 
design our analysis to account for uncontrolled timing of 
ingestion that may have resulted in women with varying pre-
dose or post-dose nevirapine concentrations, and for cases who 
changed from nevirapine to another drug after a reaction 
resulting in decreasing numbers of observations over time. This 
limitation reduced our sample size for comparisons and limited 
our ability to detect an association with rash or hepatotoxicity 
with smaller differences in pre-dose nevirapine concentrations. 
We did not conduct similar drug concentration testing among 
the Kenyan and Zambian women enrolled in this study, 
therefore we have no data on those women using this study 
design. Lastly, we did not test for other possible chemical 
causes of hepatitis such as aflatoxin exposure. 
 In conclusion, we could not demonstrate definitively that 
nevirapine concentrations after a two week lead-in dose of 200 
mg daily are associated with rash or hepatotoxicity among Thai 
women. Many patients who tolerated nevirapine well for 24 
weeks had week 2 concentrations that were much higher than 
some of those who developed rash or hepatotoxicity. It is 
unlikely that therapeutic drug monitoring after the first two 
weeks of therapy will substantively improve identification of 
patients at risk for these nevirapine-associated adverse events. 
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Table 2. Nevirapine Pre-Dose and Post-Dose Concentrations 2, 4, and 8 Weeks after Starting Treatment, Bangkok, Thailand, 
2005-2007 
 
Weeks After Starting Nevirapine-Based Antiretroviral Therapy 







Pre-Dose 54 measurements 46 measurements 36 measurements 
<3,000 21 (39) 0 (0) 5 (14) 
3,000 – 5,999 28 (52) 25 (54) 18 (50) 
6,000 – 8,999 4 (7) 15 (33) 9 (25) 
9,000 1 (2) 6 (13) 4 (11) 
Post-Dose 41 measurements 37 measurements 30 measurements 
<3,000 5 (12) 0 (0) 1 (3) 
3,000 – 5,999 18 (44) 6 (16) 11 (37) 
6,000 – 8,999 12 (29) 14 (38) 14 (47) 
9,000 6 (15) 17 (46) 4 (13) 
Pre-dose and post-dose nevirapine concentrations presented in ranges of concentrations from below the targeted minimum concentration (<3,000 ng/mL) to very high concentrations 
( 9,000 ng/mL). Participants received nevirapine 200 mg once daily for the first 2 weeks, then 200 mg twice daily thereafter. All women with specimens that could be characterized 
as pre-dose or post-dose measurements are represented. 
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